Blood biomarkers associated with cognitive decline in early stage and drug-naïve Parkinson's disease patients

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Santiago, Jose A ^a   Potashkin, Judith A ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLUCOSE; MESSENGER RNA; COATOMER PROTEIN; EFTUD2 PROTEIN, HUMAN; ELONGATION FACTOR; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; POLYPYRIMIDINE TRACT BINDING PROTEIN; PTBP1 PROTEIN, HUMAN; SMALL NUCLEAR RIBONUCLEOPROTEIN;

ADULT; AGE; AGED; ARTICLE; BLOOD EXAMINATION; BLOOD SAMPLING; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; COPZ1 GENE; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DISORDERS OF CARBOHYDRATE METABOLISM; EDUCATIONAL STATUS; EFTUD2 GENE; FEMALE; GENETIC ASSOCIATION; GLUCOSE BLOOD LEVEL; HOEHN AND YAHR SCALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MONTREAL COGNITIVE ASSESSMENT SCORE; MOVEMENT DISORDER SOCIETY REVISION OF UNIFIED PARKINSON'S DISEASE RATING SCALE; OBSERVATIONAL STUDY; PARKINSON DISEASE; PTBP1 GENE; QUANTITATIVE ANALYSIS; RATING SCALE; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEX; BLOOD; COGNITION; COGNITIVE DYSFUNCTION; COMPLICATION; GENETICS; MIDDLE AGED;

AGED; BIOMARKERS; COATOMER PROTEIN; COGNITION; COGNITIVE DYSFUNCTION; CROSS-SECTIONAL STUDIES; FEMALE; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEINS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARKINSON DISEASE; PEPTIDE ELONGATION FACTORS; POLYPYRIMIDINE TRACT-BINDING PROTEIN; RIBONUCLEOPROTEIN, U5 SMALL NUCLEAR; RNA, MESSENGER;

EID: 84955561802     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142582     Document Type: Article

References (38)

1. Martinez-Martin P, Chaudhuri KR, Rojo-Abuin JM, Rodriguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, et al. Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale. Eur J Neurol. 2015; 22(1):37-43. Epub 2013/04/24. doi: 10.1111/ene.12165 .
2. Chaudhuri KR, Sauerbier A, Rojo JM, Sethi K, Schapira AH, Brown RG, et al. The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: A simple grading system. Parkinsonism Relat Disord. 2015; 21(3):287-91. Epub 2015/01/27. doi: 10.1016/j.parkreldis. 2014.12.031 .
3. Rajput AH, Rajput A. Accuracy of Parkinson disease diagnosis unchanged in 2 decades. Neurology. 2014; 83(5):386-7. Epub 2014/07/01. doi: 10.1212/WNL.0000000000000653 .
4. Santiago JA, Potashkin JA. Current challenges towards the development of a blood test for Parkinson's disease. Diagnostics. 2014; 4(4):153-64. doi: 10.3390/diagnostics4040153
5. Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, et al. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A. 2007; 104(3):955-60. Epub 2007/01/12. doi: 10.1073/pnas.0610204104
6. Molochnikov L, Rabey JM, Dobronevsky E, Bonucelli U, Ceravolo R, Frosini D, et al. A molecular signature in blood identifies early Parkinson's disease. Mol Neurodegener. 2012; 7:26. Epub 2012/06/02. doi: 10.1186/1750-1326-7-26
7. Alieva A, Shadrina MI, Filatova EV, Karabanov AV, Illarioshkin SN, Limborska SA, et al. Involvement of endocytosis and alternative splicing in the formation of the pathological process in the early stages of Parkinson's disease. Biomed Res Int. 2014; 2014:718732. Epub 2014/05/08. doi: 10.1155/2014/718732
8. Karlsson MK, Sharma P, Aasly J, Toft M, Skogar O, Saebo S, et al. Found in transcription: Accurate Parkinson's disease classification in peripheral blood. J Parkinsons Dis. 2013; 3(1):19-29. Epub 2013/08/14. doi: 10.3233/JPD-120159 .
9. Serafin A, Foco L, Zanigni S, Blankenburg H, Picard A, Zanon A, et al. Overexpression of blood micro-RNAs 103a, 30b, and 29a in L-dopa-Treated patients with PD. Neurology. 2015; 84(7):645-53. Epub 2015/01/18. doi: 10.1212/WNL.0000000000001258 .
10. Martins M, Rosa A, Guedes LC, Fonseca BV, Gotovac K, Violante S, et al. Convergence of miRNA expression profiling, alpha-synuclein interacton and GWAS in Parkinson's disease. PLoS One. 2011; 6 (10):e25443. Epub 2011/10/18. doi: 10.1371/journal.pone.0025443
11. Potashkin JA, Santiago JA, Ravina BM, Watts A, Leontovich AA. Biosignatures for Parkinson's disease and atypical parkinsonian disorders patients. PLoS One. 2012; 7(8):e43595. Epub 2012/09/07. doi: 10. 1371/journal.pone.0043595
12. Santiago JA, Scherzer CR, Potashkin JA. Specific splice variants are associated with Parkinson's disease. Mov Disord. 2013; 28(12):1724-7. Epub 2013/10/11. doi: 10.1002/mds.25635
13. Santiago JA, Potashkin JA. Integrative network analysis unveils convergent molecular pathways in Parkinson's disease and diabetes. PLoS One. 2013; 8(12):e83940. Epub 2014/01/01. doi: 10.1371/journal.pone.0083940
14. Santiago JA, Scherzer CR, Potashkin JA. Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease. PLoS One. 2014; 9(10):e109042. Epub 2014/10/04. doi: 10.1371/journal.pone.0109042
15. Santiago JA, Potashkin JA. Network-based metaanalysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinson's disease. Proc Natl Acad Sci U S A. 2015; 112(7):2257-62. Epub 2015/02/04. doi: 10.1073/pnas.1423573112 .
16. Santiago JA, Potashkin JA. A network approach to clinical intervention in neurodegenerative diseases. Trends Mol Med. 2014; 20(12):694-703. Epub 2014/12/03. doi: 10.1016/j.molmed.2014.10.002 .
17. Infante J, Prieto C, Sierra M, Sanchez-Juan P, Gonzalez-Aramburu I, Sanchez-Quintana C, et al. Identification of candidate genes for Parkinson's disease through blood transcriptome analysis in LRRK2-G2019S carriers, idiopathic cases, and controls. Neurobiol Aging. 2015; 36(2):1105-9. Epub 2014/12/06. doi: 10.1016/j.neurobiolaging.2014.10.039 .
18. Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, et al. Association of cerebrospinal fluid beta-Amyloid 1-42, T-Tau, P-Tau181, and alpha-synuclein levels with clinical features of drugnaive patients with early Parkinson disease. JAMA Neurol. 2013; 70(10):1277-87. Epub 2013/08/28. doi: 10.1001/jamaneurol.2013.3861
19. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol. 2011; 95(4):629-35. Epub 2011/09/21. doi: 10.1016/j.pneurobio.2011.09.005 .
20. Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology. 2010; 75(19):1717-25. Epub 2010/11/10. doi: 10.1212/WNL.0b013e3181fc29c9 .
21. Weintraub D, Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A, et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Mov Disord. 2015. Epub 2015/03/05. doi: 10.1002/mds.26170 .
22. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: An 8-year prospective study. Arch Neurol. 2003; 60(3):387-92. Epub 2003/03/14. .
23. Mollenhauer B, Rochester L, Chen-Plotkin A, Brooks D. What can biomarkers tell us about cognition in Parkinson's disease? Mov Disord. 2014; 29(5):622-33. Epub 2014/04/24. doi: 10.1002/mds.25846
24. Alves G, Bronnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: The Norwegian Park-West study. J Neurol Neurosurg Psychiatry. 2010; 81(10):1080-6. Epub 2010/06/16. doi: 10.1136/jnnp.2009.199950 .
25. Liu C, Cholerton B, Shi M, Ginghina C, Cain KC, Auinger P, et al. CSF tau and tau/Abeta42 predict cognitive decline in Parkinson's disease. Parkinsonism Relat Disord. 2015; 21(3):271-6. Epub 2015/01/19. doi: 10.1016/j.parkreldis.2014.12.027 .
26. Chen-Plotkin AS, Hu WT, Siderowf A, Weintraub D, Goldmann Gross R, Hurtig HI, et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol. 2011; 69(4):655-63. Epub 2011/04/27. doi: 10.1002/ana.22271
27. Jiang QW, Wang C, Zhou Y, Hou MM, Wang X, Tang HD, et al. Plasma epidermal growth factor decreased in the early stage of Parkinson's disease. Aging Dis. 2015; 6(3):168-73. Epub 2015/06/02. doi: 10.14336/AD.2014.0925
28. Picillo M, Erro R, Santangelo G, Pivonello R, Longo K, Pivonello C, et al. Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naive Parkinson's disease. J Neurol. 2013; 260 (7):1724-30. Epub 2013/02/13. doi: 10.1007/s00415-013-6851-0 .
29. Pellecchia MT, Santangelo G, Picillo M, Pivonello R, Longo K, Pivonello C, et al. Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naive Parkinson's disease. Eur J Neurol. 2014; 21(5):802-7. Epub 2013/04/05. doi: 10.1111/ene.12137 .
30. Pellecchia MT, Santangelo G, Picillo M, Pivonello R, Longo K, Pivonello C, et al. Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients. J Neurol. 2013; 260(2):438-44. Epub 2012/08/23. doi: 10.1007/s00415-012-6648-6 .
31. La Cognata V, D'Agata V, Cavalcanti F, Cavallaro S. Splicing: is there an alternative contribution to Parkinson's disease? Neurogenetics. 2015. Epub 2015/05/20. doi: 10.1007/s10048-015-0449-x .
32. Knoch KP, Meisterfeld R, Kersting S, Bergert H, Altkruger A, Wegbrod C, et al. cAMP-dependent phosphorylation of PTB1 promotes the expression of insulin secretory granule proteins in beta cells. Cell Metab. 2006; 3(2):123-34. Epub 2006/02/07. doi: 10.1016/j.cmet.2005.12.008 .
33. Santiago JA, Potashkin JA. Shared dysregulated pathways lead to Parkinson's disease and diabetes. Trends Mol Med. 2013; 19(3):176-86. Epub 2013/02/05. doi: 10.1016/j.molmed.2013.01.002 .
34. Santiago JA, Potashkin JA. System-based approaches to decode the molecular links in Parkinson's disease and diabetes. Neurobiol Dis. 2014; 72 Pt A:84-91. Epub 2014/04/11. doi: 10.1016/j.nbd.2014. 03.019 .
35. Sandyk R. The relationship between diabetes mellitus and Parkinson's disease. Int J Neurosci. 1993; 69(1-4):125-30. Epub 1993/03/01. .
36. Boyd AE 3rd, Lebovitz HE, Feldman JM. Endocrine function and glucose metabolism in patients with Parkinson's disease and their alternation by L-Dopa. J Clin Endocrinol Metab. 1971; 33(5):829-37. Epub 1971/11/01. doi: 10.1210/jcem-33-5-829 .
37. Swanson CR, Berlyand Y, Xie SX, Alcalay RN, Chahine LM, Chen-Plotkin AS. Plasma Apolipoprotein A1 Associates With Age at Onset and Motor Severity in Early Parkinson's Disease Patients. Mov Disord. 2015. Epub 2015/07/25. doi: 10.1002/mds.26290 .
38. Chen-Plotkin AS. Unbiased approaches to biomarker discovery in neurodegenerative diseases. Neuron. 2014; 84(3):594-607. Epub 2014/12/03. doi: 10.1016/j.neuron.2014.10.031